$SNDX News
Last published 2d ago
- 2d agoSNDXSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connection with the
- 2d agoSNDXSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connection with the hiring, announced on November 2, 2026, of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026, Mr. Ondrey received an inducement award to purchase up to 270,000 shares of ...
- 1w agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 4, 2026, the
- 1w agoSNDXSyndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026GlobeNewswireNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an
- 1w agoSNDXSyndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026GlobeNewswire– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax’s scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia
- 1w agoSNDXSyndax Pharmaceuticals Inc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 5.02 Item 9.01
- 1w agoSNDXSyndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial OfficerGlobeNewswire- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage
- 1w agoSNDXSyndax Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute
- 1w agoSNDXTHIRD QUARTER 2026 EARNINGS CALL - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsGood day, everyone, and welcome to the Syndex 3rd Quarter 2026 Earnings Conference Call. Today's call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press star 5 durin
- 1w agoSNDXThird Quarter 2026 Earnings Call - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsGood day, everyone, and welcome to the Syndex 3rd Quarter 2026 Earnings Conference Call. Today's call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press star 5 durin
- 1w agoSNDXSyndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan DiseasesGlobeNewswire- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) --
- 1w agoSNDXSyndax Announces Participation in November Investor ConferencesGlobeNewswireNEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
- 2w agoSNDXSyndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026GlobeNewswireNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third
- 3w agoSNDXSyndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 ListGlobeNewswireNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the
- 1mo agoSNDXSyndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary FibrosisGlobeNewswire– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues
- 2mo agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the
- 2mo agoSNDXSyndax Announces Participation in September Investor ConferencesGlobeNewswireNEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
- 3mo agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company
- 3mo agoSNDXSecond Quarter 2026 Earnings Call - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsGood day, everyone, and welcome to the Syndex second quarter 2026 earnings conference call. Today's call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press star five
- 3mo agoSNDXSecond Quarter 2026 Earnings Call - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsGood day, everyone, and welcome to the Syndex second quarter 2026 earnings conference call. Today's call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press star five
- 3mo agoSNDXSecond Quarter 2026 Earnings Call - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsGood day, everyone, and welcome to the Syndex second quarter 2026 earnings conference call. Today's call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press star five
- 3mo agoSNDXSyndax Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3
- 3mo agoSNDXSyndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026GlobeNewswireNEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second
- 4mo agoSNDXR&D EVENT - SYNDAX PHARMACEUTICALS INCEarnings Call Transcriptsall right good morning everyone we're gonna get started so it's my pleasure to welcome you this morning my name is Michael Metzger I'm the CEO of syntax welcome warm welcome to everybody joining us in person today and al
- 4mo agoSNDXR&D EVENT - SYNDAX PHARMACEUTICALS INCEarnings Call Transcriptsall right good morning everyone we're gonna get started so it's my pleasure to welcome you this morning my name is Michael Metzger I'm the CEO of syntax welcome warm welcome to everybody joining us in person today and al
- 4mo agoSNDXSyndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D EventGlobeNewswire– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor,
- 4mo agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company
- 5mo agoSNDXSyndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026GlobeNewswire– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive
- 5mo agoSNDXSyndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical OncologyGlobeNewswire– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70%
- 5mo agoSNDXSyndax Pharmaceuticals - 1764381 - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good afternoon, everyone. Thanks again for joining us at the Goldman Sachs Global Healthcare Conference. We're thrilled to have Michael Metzger and Keith Golden, Chief Executive and Chief Financial Officer for
- 5mo agoSNDXGoldman Sachs 47th Annual Global Healthcare Conference - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good afternoon, everyone. Thanks again for joining us at the Goldman Sachs Global Healthcare Conference. We're thrilled to have Michael Metzger and Keith Golden, Chief Executive and Chief Financial Officer for
- 5mo agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company
- 5mo agoSNDXJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good morning, everyone. Thank you to those of you in the room, as well as those of you dialed in on the webcast. My name is Pasuk Rashid. I'm one of the senior biotech analysts here at Jefferies. We are here l
- 5mo agoSNDXSyndax Announces Private Placement of $250.0 Million of Convertible Senior NotesGlobeNewswireNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax") (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately
- 5mo agoSNDXSyndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant DataGlobeNewswire– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a2-year overall survival rate of 90% vs historical
- 5mo agoSNDXSyndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026GlobeNewswireNEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on
- 5mo agoSNDXTD COWEN 7TH ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FOR ASCO & EHA - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon and welcome once again to TD Cowan's 7th Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowan, and it's my pleasure to moderate a fireside chat with CINDEX. We have
- 5mo agoSNDXSyndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant DataGlobeNewswire– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring unique aspects of
- 5mo agoSNDXSyndax Announces Participation in Upcoming Investor ConferencesGlobeNewswireNEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
- 6mo agoSNDXSyndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin InhibitionGlobeNewswire– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability with revumenib
- 6mo agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026, the Company
- 6mo agoSNDXSyndax Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R
- 6mo agoSNDXSyndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026GlobeNewswireNEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first
- 7mo agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company
- 8mo agoSNDXBarclays 28th Annual Global Healthcare Conference - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsHello again, everyone. My name is Edster Darude, one of the senior biotech analysts at Barclays. It's my pleasure to have Sendax Pharmaceuticals with us for our next Fireside Chat. With me today, I have Michael Metzger,
- 8mo agoSNDXBarclays 28th Annual Global Healthcare Conference - SYNDAX PHARMACEUTICALS INCEarnings Call TranscriptsHello again, everyone. My name is Edster Darude, one of the senior biotech analysts at Barclays. It's my pleasure to have Sendax Pharmaceuticals with us for our next Fireside Chat. With me today, I have Michael Metzger,
- 8mo agoSNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1, 2026, the Company
- 8mo agoSNDXSyndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™
- 8mo agoSNDXSyndax Announces Participation in March Investor ConferencesGlobeNewswireNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
- 8mo agoSNDXSyndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026GlobeNewswireNEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth